Gene
IGF1R
IGF1R is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (47), Actionable biomarkers (1), Trial mentions (131), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention IGF1R. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 7 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 10 of 8,738 | 0.11% | not measured | |
| 2025 | 8 of 8,875 | 0.09% | not measured | |
| 2024 | 6 of 8,597 | 0.07% | not measured | |
| 2023 | 3 of 8,275 | 0.04% | 38 of 11,460 | 0.33% |
| 2022 | 5 of 8,285 | 0.06% | 49 of 13,598 | 0.36% |
| 2021 | 1 of 8,692 | 0.01% | 60 of 15,045 | 0.40% |
| 2020 | 0 of 7,640 | 0.00% | 47 of 14,459 | 0.33% |
| 2019 | 2 of 7,300 | 0.03% | 50 of 12,159 | 0.41% |
| 2018 | 1 of 6,927 | 0.01% | 45 of 11,854 | 0.38% |
| 2017 | 3 of 6,558 | 0.05% | 54 of 11,595 | 0.47% |
Showing 10 of 37 years.
Assay-provider ledger (47)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| GeneCast Biotechnology Co., Ltd | Diagnostic provider | Clinical validation | 1 | May 01, 2021 |
| Prometheus Laboratories | Diagnostic provider | Clinical validationAnalytical validation | 1 | April 11, 2017 |
| CalBiochem | Reagent supplier | Clinical validation | 1 | February 07, 2017 |
| Cell Signaling Technology | Reagent supplier | Clinical validationAnalytical validation | 2 | February 07, 2017 |
| DAKO | Unclassified | Clinical validation | 2 | February 07, 2017 +1 undated |
Showing 5 of 47 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| IGF1R amplification | Erlotinib | responsive | lung adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (131)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01122199 | Trial eligibility (AACT) |
| NCT07265258 | Trial eligibility (AACT) |
| NCT00908024 | Trial eligibility (AACT) |
| NCT01473303 | Trial eligibility (AACT) |
| NCT01605396 | Trial eligibility (AACT) |
Showing 5 of 131 trial mentions.
Target-disease associations (610)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-phosphoinositide-dependent protein kinase 1 measurement | measurement | GWAS credible sets |
| AIDS dementia | infectious disease | Literature (Europe PMC) |
| Abnormality of the immune system | phenotype | GWAS credible sets |
| Abnormality of the skeletal system | phenotype | gene burden |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
Showing 5 of 610 associations.
Vendor sourcing (319)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 1 Million 4 Anna Foundation | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Age ≥ 12 years and ≤ 50 years at time of enrollment. * Karnofsky performance status ≥ 50% for patients ≥16 years of age and Lansky ≥ 50% for patients \<... | View trial NCT04129151 |
| 1 Million 4 Anna Foundation | Trial collaborator | Mentioned in trial textTrial free-text mention | IGF1R | View trial NCT04129151 |
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Same nucleotide change resulting in same amino acid change has been previously reported to be associated with IGF1R related disorder (ClinVar ID: VCV00063584... | View ClinVar record SCV002058558.1 |
| ACELYRIN Inc. | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Pathology related to inflammatory bowel disease or irritable bowel syndrome. * Clinically significant pathology related to hearing or history of hearing... | View trial NCT05683496 |
| ACELYRIN Inc. | Trial sponsor | Mentioned in trial textTrial free-text mention | IGF1R | View trial NCT05683496 |
Showing 5 of 319 sourcing records.
Trial-cited literature (754)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management. | The lancet. Diabetes & endocrinology | 2025 | 58 |
| IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients: The RESTORE-1 Randomized Clinical Trial. | JAMA ophthalmology | 2025 | 10 |
| Identification of functional rare coding variants in IGF-1 gene in humans with exceptional longevity. | Scientific reports | 2025 | 4 |
| Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy. | Neuro-oncology | 2024 | 23 |
| Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis. | Translational oncology | 2024 | 15 |
Showing 5 of 754 papers.
Protein variant mentions (36)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A1206T | 1 | 2014 | PMID 25013076 |
| p.A701T | 1 | 2015 | PMID 25741868 |
| p.C332Y | 1 | 2015 | PMID 25741868 |
| p.E121K | 1 | 2015 | PMID 25741868 |
| p.E1356K | 1 | 2015 | PMID 25741868 |
Showing 5 of 36 variants.
Literature-extracted relations (163)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| EVEROLIMUS | Chemical | positive_correlate |
Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer. | 2018 |
| Letrozole | Chemical | negative_correlate |
Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer. | 2018 |
| PREDNISOLONE | Chemical | negative_correlate |
Effects of Prednisolone on Serum and Tissue Fluid IGF-I Receptor Activation and Post-Receptor Signaling in Humans. | 2017 |
| EVEROLIMUS | Chemical | associate |
Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. | 2015 |
| Isoflurane | Chemical | positive_correlate |
Impact of isoflurane on malignant capability of ovarian cancer in vitro. | 2015 |
Showing 5 of 163 relation assertions.
Organizations publishing (582)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| The University of Texas System | Academic | 32 | 2006 to 2024 |
| Government of the United States of America | Government | 28 | 1999 to 2024 |
| Memorial Sloan Kettering Cancer Center | Hospital | 27 | 2006 to 2024 |
| Harvard Medical School | Academic | 22 | 2004 to 2023 |
| Dana-Farber Cancer Institute | Other | 18 | 2004 to 2023 |
Showing 5 of 582 organizations.
Where IGF1R appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- psychiatric disorder
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
552 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.